Sex: F
Vaccine: COVID19
Symptoms: COVID-19 immunisation, Interchange of vaccine products, No adverse event
Clinical narrative: She received a Pfizer for her first dose but then was given a Moderna bivalent for the second dose, patient received second primary dose to complete primary series; She received a Pfizer for her first dose but then was given a Moderna bivalent for the second dose, patient received second primary dose to complete primary series; No adverse reaction; This spontaneous case was reported by a nurse and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (She received a Pfizer for her first dose but then was given a Moderna bivalent for the second dose, patient received second primary dose to complete primary series), COVID-19 IMMUNISATION (She received a Pfizer for her first dose but then was given a Moderna bivalent for the second dose, patient received second primary dose to complete primary series) and NO ADVERSE EVENT (No adverse reaction) in an adult female patient who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: PFIZER BIONTECH COVID-19 VACCINE (First dose). Past adverse reactions to the above products included No adverse event with PFIZER BIONTECH COVID-19 VACCINE.    On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (She received a Pfizer for her first dose but then was given a Moderna bivalent for the second dose, patient received second primary dose to complete primary series), COVID-19 IMMUNISATION (She received a Pfizer for her first dose but then was given a Moderna bivalent for the second dose, patient received second primary dose to complete primary series) and NO ADVERSE EVENT (No adverse reaction). At the time of the report, INTERCHANGE OF VACCINE PRODUCTS (She received a Pfizer for her first dose but then was given a Moderna bivalent for the second dose, patient received second primary dose to complete primary series), COVID-19 IMMUNISATION (She received a Pfizer for her first dose but then was given a Moderna bivalent for the second dose, patient received second primary dose to complete primary series) and NO ADVERSE EVENT (No adverse reaction) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse reaction) to be not related. No further causality assessments were provided for INTERCHANGE OF VACCINE PRODUCTS (She received a Pfizer for her first dose but then was given a Moderna bivalent for the second dose, patient received second primary dose to complete primary series) and COVID-19 IMMUNISATION (She received a Pfizer for her first dose but then was given a Moderna bivalent for the second dose, patient received second primary dose to complete primary series).    No concomitant medications were reported.  It was reported that the patient received second primary dose to complete primary series.  No adverse reactions were reported.  No treatment medications were reported.   This case was linked to MOD-2023-714821 (Patient Link).